Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.81 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.73 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | BLM | P54132 | 1/20 | 0.71 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8483664 | 0.86 | TSHR (0.67) | TSHRHSD17B10CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL29389684 | 0.85 | TSHR (1.00) | TSHRHSD17B10CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL22340503 | 0.85 | TSHR (0.67) | TSHRHSD17B10CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL693529 | 0.85 | TSHR (1.00) | TSHRHSD17B10CYP1A2CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL29390714 | 0.84 | LMNA (1.00) | TSHRHSD17B10CYP1A2CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL2268042 | 0.84 | LMNA (1.00) | TSHRHSD17B10CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL7768256 | 0.84 | TSHR (0.57) | TSHRHSD17B10CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL31153347 | 0.84 | TSHR (0.57) | TSHRHSD17B10CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL6226217 | 0.81 | PYCR1 (0.62) | TSHRHSD17B10CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL6932425 | 0.79 | TSHR (0.58) | TSHRHSD17B10CYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034798-B2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | CAPROTEC BIOANALYTICS GMBH (DE) | 2015-05-19 | — | — | US | disclosed |
| EP-1720613-A4 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF 17BETA-HYDROXYSTEROID DEHYDROGERNASE 3 | BRISTOL MYERS SQUIBB CO (US) | 2009-05-06 | — | — | EP | disclosed |
| US-7417040-B2 | Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| US-7417040-B2 | Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| US-7417040-B2 | Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| EP-1720613-A2 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF 17BETA-HYDROXYSTEROID DEHYDROGERNASE 3 | Bristol-Myers Squibb Company (US) | 2006-11-15 | — | — | EP | disclosed |
| US-20050250753-A1 | Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-10 | — | — | US | disclosed |
| WO-2005084296-A2 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF 17BETA-HYDROXYSTEROID DEHYDROGERNASE 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-15 | — | — | WO | disclosed |
| US-4057565-A | OXYGEN SCAVENGERS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1977-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250753-A1 | Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | HSD17B3, HSD17B11, HSD17B1 | TSHR 4264/4885HSD17B10 10/4885CYP1A2 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.